These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4122 related articles for article (PubMed ID: 6282111)

  • 1. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)- ethylphosphorothioic acid (WR 2721).
    Millar JL; McElwain TJ; Clutterbuck RD; Wist EA
    Am J Clin Oncol; 1982 Jun; 5(3):321-8. PubMed ID: 6282111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
    Milas L; Ito H; Hunter N
    Cancer Res; 1983 Jul; 43(7):3050-6. PubMed ID: 6303574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
    Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
    Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
    Yuhas JM
    Cancer Res; 1980 May; 40(5):1519-24. PubMed ID: 6245795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioprotection of mouse colony forming units-spleen against heavy-charged particle damage by WR 2721.
    Afzal SM; Ainsworth EJ
    Radiat Res; 1987 Jan; 109(1):118-26. PubMed ID: 3027738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of WR-2721 in radiotherapy and/or chemotherapy.
    Yuhas JM; Spellman JM; Culo F
    Cancer Clin Trials; 1980; 3(3):211-6. PubMed ID: 6254681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
    Milas L; Hunter N; Stephens LC; Peters LJ
    Cancer Res; 1984 Dec; 44(12 Pt 1):5567-9. PubMed ID: 6093999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine.
    Yuhas JM
    Cancer Treat Rep; 1979 Jun; 63(6):971-6. PubMed ID: 223759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
    Grdina DJ; Carnes BA; Grahn D; Sigdestad CP
    Cancer Res; 1991 Aug; 51(16):4125-30. PubMed ID: 1651155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of glutathione by the radioprotective agent S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR2721).
    Schor NF
    Biochem Pharmacol; 1988 Feb; 37(3):562-3. PubMed ID: 2827689
    [No Abstract]   [Full Text] [Related]  

  • 11. Protective effect of S-2-(3-aminopropylamino)ethylphosphorothioic acid against induction of altered hepatocyte foci in rats treated once with gamma-radiation within one day after birth.
    Grdina DJ; Peraino C; Carnes BA; Hill CK
    Cancer Res; 1985 Nov; 45(11 Pt 1):5379-81. PubMed ID: 2865003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat.
    Carfagna PF; Chaney SG; Chang J; Holbrook DJ
    Fundam Appl Toxicol; 1990 May; 14(4):706-19. PubMed ID: 2163338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide.
    Woolley PV; Ayoob MJ; Smith FP; Dritschilo A
    J Clin Oncol; 1983 Mar; 1(3):198-203. PubMed ID: 6321681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of WR2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo.
    DeNeve WJ; Everett CK; Suminski JE; Valeriote FA
    Cancer Res; 1988 Nov; 48(21):6002-5. PubMed ID: 2844397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice.
    Milas L; Hunter N; Reid BO; Thames HD
    Cancer Res; 1982 May; 42(5):1888-97. PubMed ID: 6279288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
    Treskes M; Boven E; van de Loosdrecht AA; Wijffels JF; Cloos J; Peters GJ; Pinedo HM; van der Vijgh WJ
    Eur J Cancer; 1994; 30A(2):183-7. PubMed ID: 8155393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721.
    Valeriote F; Tolen S
    Cancer Res; 1982 Nov; 42(11):4330-1. PubMed ID: 6290032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumors.
    Clement JJ; Johnson RK
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):539-42. PubMed ID: 6286550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of melphalan with prednisolone. Anti-tumor effect and normal tissue toxicity in laboratory systems.
    Selby PJ; Millar JL; Phelps TA; Gordon MY; Wilkinson R; McElwain TJ
    Cancer Chemother Pharmacol; 1981; 6(2):169-73. PubMed ID: 7307234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Protective effects of WR2721 on early bone marrow hematopoietic function in mice exposed to 6.5 Gy of (60)Co γ-rays].
    Deng ZL; Zhang LZ; Cong Y; Liu XL; Yu ZY; Shan YJ; Cui Y; Wang LM; Xing S; Cong YW; Luo QL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):791-6. PubMed ID: 24989296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 207.